Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases $15,540.00 in Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. purchased 6,000 shares of the business’s stock in a transaction dated Tuesday, January 21st. The shares were bought at an average price of $2.59 per share, with a total value of $15,540.00. Following the purchase, the director now directly owns 928,334 shares of the company’s stock, valued at approximately $2,404,385.06. The trade was a 0.65 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Anixa Biosciences Price Performance

Shares of ANIX stock opened at $2.92 on Friday. The business’s fifty day moving average price is $2.76 and its 200 day moving average price is $3.03. The firm has a market capitalization of $94.02 million, a PE ratio of -7.49 and a beta of 0.90. Anixa Biosciences, Inc. has a 1-year low of $2.07 and a 1-year high of $4.94.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. Equities research analysts expect that Anixa Biosciences, Inc. will post -0.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, November 19th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research note on Wednesday.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ANIX. Virtu Financial LLC purchased a new stake in shares of Anixa Biosciences during the 3rd quarter worth approximately $34,000. Westside Investment Management Inc. raised its holdings in Anixa Biosciences by 151.8% during the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after purchasing an additional 21,100 shares during the last quarter. Tyler Stone Wealth Management boosted its position in Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after purchasing an additional 21,008 shares in the last quarter. Finally, International Assets Investment Management LLC boosted its position in Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares in the last quarter. 29.13% of the stock is owned by hedge funds and other institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.